Table 1 Comparison of baseline characteristics by TyG index and hsCAR grouping.

From: Triglyceride-glucose index and hsCRP-to-albumin ratio as predictors of major adverse cardiovascular events in STEMI patients with hypertension

 

Total n = 699

TyG index < 7.8

TyG index ≥ 7.8

P value

hsCAR < 0.15 n = 204

hsCAR ≥ 0.15 n = 267

hsCAR < 0.15 n = 81

hsCAR ≥ 0.15 n = 147

Age (years)

66.0 (58.0, 73.0)

66.0 (57.0, 72.0)

69.0 (61.0, 75.0)

62.0 (54.0, 69.0)

64.0 (56.0, 71.0)

< 0.001

Female, n(%)

181 (25.9%)

51 (25.0%)

68 (25.5%)

19 (23.5%)

43 (29.3%)

 

BMI (kg/m2)

25.0 (23.0, 28.0)

24.0 (23.0, 27.0)

25.0 (23.0, 28.0)

26.0 (24.0, 28.0)

26.0 (24.0, 29.0)

< 0.001

Heart rate (bpm)

78.0 (69.0, 90.0)

76.0 (66.0, 85.5)

78.0 (69.0, 91.0)

77.0 (70.0, 88.0)

83.0 (72.0, 95.0)

< 0.001

SBP (mmHg)

145.0 (128.0, 159.0)

146.0 (129.5, 159.0)

143.0 (125.0, 156.0)

147.0 (134.0, 160.0)

149.0 (126.0, 165.0)

0.035

DBP (mmHg)

87.0 (77.0, 98.0)

88.0 (80.0, 99.0)

83.0 (72.0, 93.0)

90.0 (80.0, 98.0)

89.0 (76.0, 99.0)

< 0.001

Current smoking, n(%)

304 (43.5%)

81 (39.7%)

122 (45.7%)

36 (44.4%)

65 (44.2%)

0.62

Diabetes, n(%)

243 (34.8%)

47 (23.0%)

75 (28.1%)

39 (48.1%)

82 (55.8%)

< 0.001

Stroke, n(%)

119 (17.0%)

32 (15.7%)

55 (20.6%)

11 (13.6%)

21 (14.3%)

0.27

Interventions

Stent, n(%)

624 (89.3%)

190 (93.1%)

234 (87.6%)

69 (85.2%)

131 (89.1%)

0.13

0

72 (10.3%)

13 (6.4%)

31 (11.6%)

12 (14.8%)

16 (10.9%)

0.22

1

379 (54.2%)

120 (58.8%)

134 (50.2%)

44 (54.3%)

81 (55.1%)

 

≥ 2

248 (35.5%)

71 (34.8%)

102 (38.2%)

25 (30.9%)

50 (34.0%)

 

SYNTAX score

18.5 (13.0, 24.5)

16.3 (11.0, 22.0)

19.0 (13.0, 25.0)

18.5 (13.5, 24.5)

19.5 (13.0, 26.5)

0.002

rSS

7.0 (3.0, 12.0)

5.0 (1.0, 11.0)

8.0 (3.0, 12.0)

9.0 (5.0, 12.0)

7.0 (3.0, 12.0)

0.012

GRACE score

141.0 (123.0, 163.0)

137.0 (119.5, 154.0)

153.0 (132.0, 170.0)

129.0 (112.0, 144.0)

139.0 (120.0, 159.0)

< 0.001

LVEF (%)

48.0 (42.0, 55.0)

50.0 (44.0, 57.0)

47.0 (42.0, 53.0)

50.0 (44.0, 57.0)

46.0 (40.0, 53.0)

< 0.001

Platelet (*109/L)

222.0 (186.0, 263.0)

219.0 (185.0, 264.0)

224.0 (186.0, 267.0)

218.0 (188.0, 262.0)

220.0 (183.0, 259.0)

0.91

Hemoglobin (g/L)

145.0 (131.0, 156.0)

147.0 (133.5, 156.0)

140.0 (127.0, 153.0)

150.0 (139.0, 157.0)

146.0 (132.0, 160.0)

0.001

eGFR (ml/min/1.73m2)

89.7 (72.8, 106.5)

92.5 (80.8, 108.0)

88.7 (70.5, 105.3)

91.4 (72.8, 115.0)

84.8 (67.0, 101.2)

0.003

Serum albumin (g/L)

39.0 (36.0, 44.0)

41.0 (38.0, 45.0)

37.0 (34.0, 42.0)

42.0 (39.0, 45.0)

39.0 (35.0, 45.0)

< 0.001

FBG (mmol/L)

6.4 (5.4, 8.5)

5.7 (5.1, 6.7)

5.9 (5.2, 7.1)

8.0 (6.4, 10.8)

9.6 (7.2, 12.8)

< 0.001

HbA1C (%)

6.2 (5.7, 7.3)

5.9 (5.5, 6.5)

6.0 (5.6, 6.7)

6.9 (5.9, 8.8)

7.7 (6.3, 9.3)

< 0.001

hs-CRP (mg/L)

7.4 (3.5, 15.4)

2.7 (1.5, 4.1)

13.8 (8.7, 30.2)

3.2 (2.0, 4.2)

12.3 (9.0, 25.8)

< 0.001

BNP (pg/mL)

77.2 (25.5, 282.0)

53.2 (17.9, 109.5)

196.0 (57.0, 443.0)

40.4 (14.0, 74.8)

88.2 (28.6, 408.0)

< 0.001

TC (mmol/L)

183.0 (154.0, 212.0)

177.0 (155.0, 206.5)

171.0 (144.0, 200.0)

190.0 (169.0, 220.0)

200.0 (171.0, 231.0)

< 0.001

TG (mmol/L)

145.0 (111.0, 201.0)

127.0 (99.5, 157.0)

125.0 (97.0, 157.0)

234.0 (176.0, 293.0)

224.0 (170.0, 302.0)

< 0.001

LDL-C (mmol/L)

115.0 (94.0, 140.0)

113.0 (93.0, 137.0)

110.0 (84.0, 134.0)

117.0 (104.0, 141.0)

127.0 (103.0, 152.0)

< 0.001

HDL-C (mmol/L)

39.0 (34.0, 46.0)

41.5 (36.0, 48.0)

39.0 (34.0, 46.0)

38.0 (33.0, 42.0)

38.0 (32.0, 44.0)

< 0.001

TyG index

7.5 (7.1, 7.9)

7.2 (7.0, 7.5)

7.3 (7.0, 7.5)

8.1 (7.9, 8.3)

8.2 (8.0, 8.6)

< 0.001

hsCAR (mg/L)

0.19 (0.09, 0.40)

0.07 (0.04, 0.10)

0.37 (0.22, 0.80)

0.08 (0.05, 0.10)

0.31 (0.22, 0.65)

< 0.001

P2Y12 inhibitor

Clopidogrel, n(%)

418 (59.8%)

137 (67.2%)

137 (51.3%)

58 (71.6%)

86 (58.5%)

< 0.001

Ticagrelor, n(%)

281 (40.2%)

67 (32.8%)

130 (48.7%)

23 (28.4%)

61 (41.5%)

 

Statin

Rosuvastatin, n(%)

618 (88.4%)

179 (87.7%)

235 (88.0%)

70 (86.4%)

134 (91.2%)

0.67

Atorvastatin, n(%)

81 (11.6%)

25 (12.3%)

32 (12.0%)

11 (13.6%)

13 (8.8%)

 

ACEI/ARB/ARNI, n(%)

285 (40.8%)

75 (36.8%)

104 (39.0%)

37 (45.7%)

69 (46.9%)

0.18

Beta blocker, n(%)

442 (63.2%)

123 (60.3%)

163 (61.0%)

57 (70.4%)

99 (67.3%)

0.25

PCSK9i, n(%)

101 (14.4%)

24 (11.8%)

35 (13.1%)

15 (18.5%)

27 (18.4%)

0.21

SGLT2i, n(%)

152 (21.7%)

24 (11.8%)

52 (19.5%)

22 (27.2%)

54 (36.7%)

< 0.001

MACE, n(%)

316 (45.2%)

57 (27.9%)

112 (41.9%)

37 (45.7%)

110 (74.8%)

< 0.001

  1. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; rSS: residual SYNTAX score; LVEF: left ventricular ejection fraction; FBG: fasting blood glucose; hs-CRP: high-sensitivity C-reactive protein; BNP: B-type natriuretic peptide; TC: total cholesterol; TG: triglyceride; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; hsCAR: high-sensitivity C-reactive protein-to-albumin ratio; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; ARNI: angiotensin receptor and neprilysin inhibitor; PCSK9i: PCSK9 inhibitor; SGLT2i: sodium–glucose cotransporter 2 inhibitor; MACE: major adverse cardiovascular events.
Back to article page